Contineum Therapeutics (CTNM) Enterprise Value (2023 - 2025)
Historic Enterprise Value for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to -$182.4 million.
- Contineum Therapeutics' Enterprise Value rose 1472.76% to -$182.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$182.4 million, marking a year-over-year increase of 1472.76%. This contributed to the annual value of -$204.8 million for FY2024, which is 6355.94% down from last year.
- Contineum Therapeutics' Enterprise Value amounted to -$182.4 million in Q3 2025, which was up 1472.76% from -$175.5 million recorded in Q2 2025.
- In the past 5 years, Contineum Therapeutics' Enterprise Value registered a high of -$117.9 million during Q1 2024, and its lowest value of -$218.7 million during Q2 2024.
- Over the past 3 years, Contineum Therapeutics' median Enterprise Value value was -$186.6 million (recorded in 2025), while the average stood at -$178.6 million.
- In the last 5 years, Contineum Therapeutics' Enterprise Value plummeted by 6355.94% in 2024 and then soared by 1974.32% in 2025.
- Over the past 3 years, Contineum Therapeutics' Enterprise Value (Quarter) stood at -$125.2 million in 2023, then crashed by 63.56% to -$204.8 million in 2024, then rose by 10.92% to -$182.4 million in 2025.
- Its Enterprise Value stands at -$182.4 million for Q3 2025, versus -$175.5 million for Q2 2025 and -$190.7 million for Q1 2025.